ReviewCancer research2023
Structural and Functional Impact of Posttranslational Modification of Glypican-3 on Liver Carcinogenesis.
Review in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Generation of GPC-3-targeted radicals for precise therapy of hepatocellular carcinoma.Nature communications · 2026Article
- Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer.Journal of pharmaceutical analysis · 2026Article
- An endoplasmic reticulum membrane-mimetic GPC3 mRNA nanovaccine for specific immunotherapy of hepatocellular carcinoma.Communications biology · 2026Article
- Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.JHEP reports : innovation in hepatology · 2026Article
- Explainable machine learning-based multiphase contrast-enhanced CT radiomics for noninvasively predicting GPC3 expression in hepatocellular carcinoma: a bicentric study.American journal of translational research · 2026Article
- Navigating second-line therapy after immunotherapy in advanced HCC☆.JHEP reports : innovation in hepatology · 2026Review
- Research on Anti-tumor Pharmacodynamics of Multi-functional Magnetic Lipid Polymer with Specific Targeted Transmission of siRNA and its Toxicity Evaluation.Current pharmaceutical design · 2026Article
- Comprehensive management of advanced lymphoepithelioma-like hepatocellular carcinoma with immune-related colitis: a case report and literature review.Frontiers in oncology · 2026Article
- Noninvasive prediction of Glypican-3 expression in hepatocellular carcinoma using Habitat-based and peritumoral CT radiomics: a nomogram approach.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.Journal of clinical and translational hepatology · 2025Review
- Advancing liver cancer treatment with dual-targeting CAR-T therapy.Journal of nanobiotechnology · 2025Article
- Therapeutic Glypican-3 CRISPR Genome-Editing Using UltraLarge Porous Silica Nano-Depot for the Treatment of Hepatocellular Carcinoma.Small science · 2025Article
- Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma.Materials today. Bio · 2025Article
- Interaction of STIL with FOXM1 regulates SF3A3 transcription in the hepatocellular carcinoma development.Cell division · 2025Article
- A novel dynamic nomogram based on contrast-enhanced computed tomography radiomics for prediction of glypican-3-positive hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging.ACS pharmacology & translational science · 2024Article
- GPC3-mediated metabolic rewiring of diabetic mesenchymal stromal cells enhances their cardioprotective functions via PKM2 activation.iScience · 2024Article
- Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024Article
- Sandwich-type supersensitive electrochemical aptasensor of glypican-3 based on PrGO-Hemin-PdNP and AuNP@PoPD.Mikrochimica acta · 2024Article
- Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates.Molecular cancer therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Glypican-3 (GPC3) is a cell-surface glycoprotein that is frequently overexpressed in hepatocellular carcinoma (HCC). GPC3 undergoes extensive posttranslational modification (PTM) including cleavage and glycosylation. This review focuses on the structure and function of GPC3 in liver cancer, highlighting the PTM of the tertiary and quaternary structures of GPC3 as a potential oncogenic regulatory mechanism. We propose that the function of GPC3 in normal development can vary with extensive PTM and that dysregulation of these processes leads to disease. Defining the regulatory impact of these modifications can provide a deeper understanding of the role of GPC3 in oncogenesis, epithelial-mesenchymal transition, and drug development. Through review of current literature, this article provides a unique perspective on the role of GPC3 in liver cancer, focusing on potential regulatory mechanisms of PTM on GPC3 function at the molecular, cellular, and disease level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.